Loading organizations...
§ Private Profile · Toronto, Canada
Reunion Neuroscience is a technology company.
Reunion Neuroscience is a clinical-stage biopharmaceutical company focused on developing innovative, patented serotonergic psychedelic therapeutic solutions. The company's primary focus is on creating safe, fast-acting, and short-duration therapies to address various underserved mental health conditions. Their lead candidate, luvesilocin (RE104), is a patented prodrug of 4-OH-DiPT, designed to target the serotonin 2A receptor, which is recognized for its role in the antidepressant effects of psychedelic compounds.
The company was established in 2019 by industry entrepreneurs and scientific leaders who recognized the potential of psychedelic research. This team leveraged decades of promising data in mental health to develop a novel approach. Their founding insight was to refine and optimize these compounds into stable, regulated therapies, aiming to provide a new generation of treatments with improved patient outcomes and a quicker return to daily activities.
Reunion Neuroscience serves patients grappling with challenging psychiatric conditions, including postpartum depression, adjustment disorder, and generalized anxiety disorder, whose needs are not met by current standards of care. The company’s vision is to advance neuroscience to create a world where mental and emotional well-being is the baseline. They are committed to relentlessly pursuing therapeutics that offer durable antidepressive effects for millions of individuals.
Reunion Neuroscience has raised $233.0M across 2 funding rounds.
Reunion Neuroscience has raised $233.0M in total across 2 funding rounds.
Reunion Neuroscience has raised $233.0M across 2 funding rounds. Most recently, it raised $130.0M Series A in September 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2025 | $130M Series A | — | General Catalyst, MPM Capital | Announced |
| May 2, 2024 | $103M Series A | Ansbert Gadicke, Natalie Sacks | Arkin BIO Ventures, Femhealth Ventures, Mitsui & CO. Global Investment, Palo Santo, Plaisance Capital Management | Announced |
Reunion Neuroscience has raised $233.0M in total across 2 funding rounds.
Reunion Neuroscience's investors include General Catalyst, MPM Capital, Ansbert Gadicke, Natalie Sacks, Arkin Bio Ventures, FemHealth Ventures, Mitsui & Co. Global Investment, Palo Santo, Plaisance Capital Management.
Reunion Neuroscience is a clinical-stage biopharmaceutical company developing next-generation psychedelic-inspired therapeutics to treat underserved mental health disorders, such as postpartum depression (PPD) and adjustment disorder (AjD).[1][4] Its lead product candidate, RE104, a patented 4-OH-DiPT prodrug, targets safe, fast-acting, short-duration relief for PPD in the ongoing RECONNECT Phase 2 trial and AjD in cancer patients in the planned REKINDLE Phase 2 trial, while a discovery-stage asset, RE245, advances as a non-psychedelic serotonergic neuroplastogen for chronic treatments.[1][4] The company serves patients with limited treatment options, addressing unmet needs in mental health by enabling rapid return to daily activities, and has shown growth through a $103 million Series A financing in 2024 co-led by MPM BioImpact and Novo Holdings, funding clinical expansion.[1][3]
Founded in 2022 and based in Ontario, Canada, Reunion Neuroscience emerged from prior iterations, transitioning to a private company in August 2023 under CEO Greg Mayes, who previously led a take-private acquisition.[3][5] Mayes, with extensive neuroscience drug development experience, refocused the team on psychedelic-inspired solutions after the company went private, enabling a transformative $103 million Series A in May 2024 to support RE104's Phase 2 trials.[1][3] Early traction included de-risking investments by advancing RE104 for PPD and mental health distress in cancer patients, dispelling psychedelic stigma through rigorous science, and securing cornerstone funding from MPM BioImpact.[3]
Reunion Neuroscience rides the wave of psychedelic medicine resurgence, targeting mental health crises where traditional antidepressants fall short, amid growing acceptance of serotonergic therapies.[1][4] Timing aligns with regulatory progress in psychedelics and rising demand for rapid, tolerable treatments for PPD—affecting 1 in 7 mothers—and AjD in cancer patients, fueled by post-pandemic mental health awareness and investor interest in neuroplastogens.[1][3] Market forces like unmet needs in neuropsychiatry and biotech funding for de-risked assets favor Reunion, as it influences the ecosystem by pioneering short-duration options and presenting at forums like the 2025 Neuroscience Innovation Forum, potentially accelerating FDA-approved innovations.[1]
Reunion Neuroscience is poised to advance RE104 through RECONNECT topline data and initiate REKINDLE for AjD, with RE245 entering preclinical milestones in 2025, supported by its Series A runway.[1][2] Trends like psychedelic destigmatization, AI-driven drug design, and expanded insurance for mental health therapies will shape its path, potentially evolving its influence from niche innovator to leader in serotonergic treatments. As a post-privatization biotech with strong clinical momentum, it exemplifies resilient growth in neuropharma, revolutionizing care for millions underserved by legacy options.[1][3]